BRPI0907028B8 - uso de 17a-acetóxi-11ß-[4-n,n-dimetilamino-fenil)-19-norpregna-4,9-dieno-3,20-diona - Google Patents

uso de 17a-acetóxi-11ß-[4-n,n-dimetilamino-fenil)-19-norpregna-4,9-dieno-3,20-diona

Info

Publication number
BRPI0907028B8
BRPI0907028B8 BRPI0907028A BRPI0907028A BRPI0907028B8 BR PI0907028 B8 BRPI0907028 B8 BR PI0907028B8 BR PI0907028 A BRPI0907028 A BR PI0907028A BR PI0907028 A BRPI0907028 A BR PI0907028A BR PI0907028 B8 BRPI0907028 B8 BR PI0907028B8
Authority
BR
Brazil
Prior art keywords
diene
norpregna
acetoxy
dimethylamino
phenyl
Prior art date
Application number
BRPI0907028A
Other languages
English (en)
Inventor
Ulmann André
Blithe Diana
Gainer Erin
Nieman Lynnette
Original Assignee
Hra Pharma Lab
Richter Gedeon Nyrt
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40551565&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0907028(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hra Pharma Lab, Richter Gedeon Nyrt, Us Health filed Critical Hra Pharma Lab
Publication of BRPI0907028A2 publication Critical patent/BRPI0907028A2/pt
Publication of BRPI0907028A8 publication Critical patent/BRPI0907028A8/pt
Publication of BRPI0907028B1 publication Critical patent/BRPI0907028B1/pt
Publication of BRPI0907028B8 publication Critical patent/BRPI0907028B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

uso de 17(alfa)-acetóxi-11(beta)-[4-n,n-dimetilamino-fentil)-19-norpregna-4,9-dieno-3,20-diona a invenção refere-se ao uso de uma quantidade eficaz de 17(alfa)-acetóxi-11(beta)-[4-n, n-dimetilamino-fenil)-19-norpregna- 4, 9- dieno-3, 20-dieno (acetato de ulipristal) ou de qualquer metabolito desse para produzir um medicamento para tratamento de fibroldes uterinos, mais especificamente, o medicamento é útil para reduzir ou interromper o sangramento em uma paciente afligida com fibroides uterinos, e/ou para reduzir o tamanho dos fibroides uterinos.
BRPI0907028A 2008-01-29 2009-01-28 uso de 17a-acetóxi-11ß-[4-n,n-dimetilamino-fenil)-19-norpregna-4,9-dieno-3,20-diona BRPI0907028B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/021,610 2008-01-29
US12/021,610 US8299050B2 (en) 2008-01-29 2008-01-29 Method for treating uterine fibroids
PCT/EP2009/050961 WO2009095418A1 (en) 2008-01-29 2009-01-28 Use of ulipristal for treating uterine fibroids

Publications (4)

Publication Number Publication Date
BRPI0907028A2 BRPI0907028A2 (pt) 2015-07-07
BRPI0907028A8 BRPI0907028A8 (pt) 2019-08-13
BRPI0907028B1 BRPI0907028B1 (pt) 2019-09-24
BRPI0907028B8 true BRPI0907028B8 (pt) 2021-05-25

Family

ID=40551565

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907028A BRPI0907028B8 (pt) 2008-01-29 2009-01-28 uso de 17a-acetóxi-11ß-[4-n,n-dimetilamino-fenil)-19-norpregna-4,9-dieno-3,20-diona

Country Status (20)

Country Link
US (5) US8299050B2 (pt)
EP (2) EP2252301B1 (pt)
JP (2) JP5906016B2 (pt)
KR (2) KR101571400B1 (pt)
AU (1) AU2009209652B2 (pt)
BR (1) BRPI0907028B8 (pt)
CA (2) CA2713254C (pt)
CY (1) CY1116485T1 (pt)
DK (1) DK2252301T3 (pt)
ES (1) ES2450592T3 (pt)
HR (1) HRP20140132T1 (pt)
IL (2) IL207182A (pt)
MX (1) MX2010008270A (pt)
NZ (1) NZ587439A (pt)
PL (1) PL2252301T3 (pt)
PT (1) PT2252301E (pt)
SI (1) SI2252301T1 (pt)
TW (1) TWI445537B (pt)
WO (1) WO2009095418A1 (pt)
ZA (1) ZA201006049B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
JP5894143B2 (ja) * 2010-03-22 2016-03-23 リプロス セラピューティクス インコーポレイテッド 抗黄体ホルモンの無毒送達のための組成物および方法
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
EP2545922A1 (en) * 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
EP2641602A1 (en) * 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
WO2014050105A1 (en) * 2012-09-28 2014-04-03 Aska Pharmaceutical Co., Ltd. Amorphous ulipristal acetate
FR2997628B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
TWI669134B (zh) * 2012-12-14 2019-08-21 法商Ｈｒａ實驗製藥股份有限公司 銅子宮內系統
CN103006595B (zh) * 2012-12-25 2018-04-06 江苏亚邦爱普森药业有限公司 制备醋酸优力司特片的方法
EP2961412A4 (en) * 2013-02-26 2016-11-09 Triact Therapeutics Inc CANCER THERAPY
EP2983672A2 (en) 2013-04-10 2016-02-17 PregLem S.A. Progesteron receptor modulators for use in the therapy of uterine fibroids
US10444958B2 (en) * 2013-09-23 2019-10-15 Adobe Systems Incorporated Visual example-based user interface for adjusting photos along two dimensions
JP2018502061A (ja) 2014-11-24 2018-01-25 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッドＲａｍｏｔ Ａｔ Ｔｅｌ Ａｖｉｖ Ｕｎｉｖｅｒｓｉｔｙ Ｌｔｄ． 子宮筋腫の治療のための色素上皮由来因子（ｐｅｄｆ）
WO2017216637A2 (en) 2017-08-04 2017-12-21 Alvogen Malta Operations (Row) Ltd Tablet form including ulipristal acetate and the methods for its preparation
KR102086827B1 (ko) * 2017-12-14 2020-03-10 경희대학교 산학협력단 자궁근육종 치료용 울리프리스탈 아세테이트
KR102043349B1 (ko) * 2018-01-10 2019-11-12 경희대학교 산학협력단 대장암 치료 용도의 울리프리스탈 아세테이트
WO2021166001A1 (en) 2020-02-19 2021-08-26 Velfag Ehf. Device and method for filleting and pin-bone removal

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5468741A (en) * 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
EP0806952B1 (de) * 1995-02-02 2003-04-02 Schering Aktiengesellschaft Verwendung von kompetitiven progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
CA2668824A1 (en) 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secre Tary Of The Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
AU747710B2 (en) * 1997-11-14 2002-05-23 Akzo Nobel N.V. Progestogen-antiprogestogen regimens
US6262042B1 (en) * 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
FR2827517B1 (fr) 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
ES2212912B1 (es) * 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
WO2004078709A2 (en) 2003-02-28 2004-09-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHOD FOR PREPARING 17 α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES THEREOF, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES
BRPI0513141A (pt) 2004-07-09 2008-04-29 Population Council Inc composição para anel vaginal, e, processo de contracepção a longo prazo
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
CA2623678A1 (en) 2005-09-29 2007-04-05 Repros Therapeutics Inc. Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
CA2672888A1 (en) 2006-12-28 2008-07-10 Repros Therapeutics Inc. Methods and formulations for improved bioavailability of antiprogestins
PT2148681E (pt) 2007-04-20 2016-06-17 Preglem Sa Moduladores seletivos da progesterona no tratamento da hemorragia uterina
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids

Also Published As

Publication number Publication date
KR20150055626A (ko) 2015-05-21
PT2252301E (pt) 2014-02-24
TW200944211A (en) 2009-11-01
HRP20140132T1 (hr) 2014-05-09
JP6138838B2 (ja) 2017-05-31
WO2009095418A1 (en) 2009-08-06
JP2011510949A (ja) 2011-04-07
KR20110021709A (ko) 2011-03-04
PL2252301T3 (pl) 2014-07-31
ES2450592T3 (es) 2014-03-25
DK2252301T3 (en) 2014-02-17
ZA201006049B (en) 2011-05-25
US9180133B2 (en) 2015-11-10
KR101571400B1 (ko) 2015-11-24
AU2009209652A1 (en) 2009-08-06
BRPI0907028A8 (pt) 2019-08-13
EP2252301B1 (en) 2013-12-11
IL234149B (en) 2019-02-28
MX2010008270A (es) 2011-01-14
EP2684565B1 (en) 2019-10-02
CA2713254A1 (en) 2009-09-06
CY1116485T1 (el) 2017-03-15
CA2713254C (en) 2014-10-07
US20170246189A1 (en) 2017-08-31
EP2252301A1 (en) 2010-11-24
US20090192130A1 (en) 2009-07-30
IL207182A0 (en) 2010-12-30
CA2857798A1 (en) 2009-09-06
SI2252301T1 (sl) 2014-05-30
US20160022698A1 (en) 2016-01-28
IL207182A (en) 2015-06-30
US9682088B2 (en) 2017-06-20
EP2684565A1 (en) 2014-01-15
JP5906016B2 (ja) 2016-04-20
US20130023506A1 (en) 2013-01-24
IL234149A0 (en) 2014-09-30
BRPI0907028A2 (pt) 2015-07-07
AU2009209652B2 (en) 2013-03-21
NZ587439A (en) 2012-06-29
BRPI0907028B1 (pt) 2019-09-24
JP2015120711A (ja) 2015-07-02
US20140187525A1 (en) 2014-07-03
TWI445537B (zh) 2014-07-21
US8722653B2 (en) 2014-05-13
US8299050B2 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
BRPI0907028B8 (pt) uso de 17a-acetóxi-11ß-[4-n,n-dimetilamino-fenil)-19-norpregna-4,9-dieno-3,20-diona
BR112014020188A8 (pt) Dispositivo médico para uso com um material de enchimento para ocupar temporariamente um espaço dentro de um corpo do paciente para tratar obesidade
BRPI0717462A2 (pt) Emprego de valerato de estradiol ou 17 beta- estradiol em combinação com dienogest na terapia oral para manutenção e/ou aumento da libido feminin
BR112012015696A2 (pt) composição líquida anídrica antitranspirante/desodorante
BRPI0713257B8 (pt) sistema terapêutico transdérmico para a aplicação de norelgestromina
PH12013501790B1 (en) Use of dpp iv inhibitors
BRPI0918139A2 (pt) composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos e uso
BR112012022214A2 (pt) métodos e composições para tratar doença de degos
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
CU20130069A7 (es) Derivados de 2,3-dihidroimidazo[1,2-c] quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermeddes asociadas a la angiogénesis
BRPI1010277A2 (pt) Dispositivos médicos com particulados galvânicos
BRPI1011031A2 (pt) sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste.
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
AR064149A1 (es) Sal fumarato de (alfa s , beta r)-6 bromo- alfa-[ 2(dimetilamino ) etil)-2- metoxi - alfa-1-naftalenil- beta- fenil-3- quinolinaetanol
CL2007000345A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes.
BR112012024359A2 (pt) contorção de um aparelho eletrônico
EP2179737A3 (en) Modulating responsiveness to steroids
BRPI0919013A2 (pt) Dispositivo e sistema de implante pélvico
BR112016013754A2 (pt) Recaptação de serotonina-norepinefrina inibidores (irsns) e combinações dos ligantes do receptor sigma
BRPI0520258A2 (pt) uso de uma composição farmacêutica, método para preparar uma composição farmacêutica, e, uso de uma quantidade eficaz de acetato de eslicarbazepina
BR112015000321A2 (pt) formulações de laquinimod sem agente alcalinizante
BR112013004562A2 (pt) 2-óxi-quinolina-3-carboxamidas substituídas como moduladores kcnq2/3
BR112015013374A2 (pt) dispositivo de luva hemostática e método para uso do mesmo
BR112012018765A2 (pt) agente profilático ou terapêutico para as doenças do trato biliar
BRPI0602397C1 (pt) composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: RICHTER GEDEON NYRT. (HU)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/01/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF